MASH / MASLD

Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.

Njei explains the utility of Fibro-GPT for detecting advanced fibrosis and predicting hepatic decompensation in MASLD.

Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.

High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.

The Q3 recap for hepatology spotlights key FDA news, the withdrawal of OCA for PBC, and notable hepatic research from the past few months.

Researchers unveil Bobcat339, a targeted molecule that selectively eliminates pathogenic macrophages.

Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.

Janovsky describes the importance of early identification, the new treatment options available for MASH, and the continued importance of diet and exercise.

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

Saggese describes recent evolutions in MASH care with the FDA approval of semaglutide and the continued importance of diet, physical activity, and weight management.

For the first time, the FDA has accepted the initiation of the qualification of an NIT as a noninvasive surrogate endpoint in drug development for MASH.

Check out expert perspectives on semaglutide’s FDA approval for MASH and new research on PBC, infectious disease screening, and more in this August 2025 recap.

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

This episode highlights the groundbreaking approval of semaglutide for metabolic dysfunction-associated steatohepatitis, as well as GoodRx’s new Ozempic pricing.

Hosts Nancy Reau and Kimberly Brown are joined by Mary Rinella to discuss the evolving MASH treatment landscape with GLP-1s and FGF21s in development.

The accelerated approval is based on findings from Part 1 of the ESSENCE trial and indicates the agent for noncirrhotic MASH with moderate to advanced fibrosis.

Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.

Study findings suggest significant sex disparities in liver complication risk among adult patients with cirrhosis, especially in the context of nonviral cirrhosis.

Holden describes the importance of including SLD in global health policy frameworks and how a side event at the 78th WHA sought to address current gaps.

Sanyal describes the growing burden of SLD and its connection to other major chronic diseases, underscoring the need for better recognition and prevention efforts.

The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.

The Q2 recap for hepatology spotlights regulatory approvals, clinical trial updates, and the launch of HCPLive’s flagship hepatology podcast.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.